Showing posts with label 2-year advanced melanoma survival benefit with dabrafenib. Show all posts
Showing posts with label 2-year advanced melanoma survival benefit with dabrafenib. Show all posts
Saturday, October 31, 2015

2-year advanced melanoma survival benefit with dabrafenib, trametinib combination

›
Updated results from the COMBI-v trial show significantly improved overall and progression-free survival (OS, PFS) with first-line d...